CYTOKINETICS INC (CYTK)
A
Pipeline Grade
Financial Position (from SEC Filings)
$133.0M
Cash & Equivalents
$145.5M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$9,600M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
AFICAMTEN
MYQORZO |
APPROVED | Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Angina Pectoris, Breast Neoplasms, Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction, Chronic Obstructive Pulmonary Disease (COPD), Echocardiogram, Healthy Adult Subjects, Healthy Participants, Healthy Subjects, Healthy Volunteer, Heart Failure, Heart Failure With Reduced Ejection Fraction, History of Chronic Heart Failure, Hodgkin's Disease, Hypertrophic Cardiomyopathy (HCM), Intermittent Claudication, Left Ventricular Ejection Fraction, Left Ventricular Systolic Dysfunction, Mobility Limitation, Modified Release Oral Formulation, Myasthenia Gravis, Myocardial Ischemia, Non-Hodgkin's Lymphoma, Obstructive Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy (oHCM), Pediatric, Peripheral Artery Disease, Pharmacokinetics, QT Intervals Changes, QTc Intervals Changes, Spinal Muscular Atrophy, Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), Symptomatic Hypertrophic Cardiomyopathy (HCM) |
Upcoming Catalysts
No upcoming catalysts detected for this company.